KIRhub 2.0
Sign inResearch Use Only

DDR2

Sign in to save this workspace

UniProt Q16832 · PDB · AlphaFold · Substrate: AXLtide + Mn · Clone: aa 422-855high-confidence target

Top inhibitors

#DrugInhibitionResidualKISSGini
1Ponatinib100.0%0.0%78.230.534
2Nintedanib100.0%0.0%90.230.608
3Cabozantinib100.0%0.0%92.730.751
4Nilotinib99.7%0.3%96.490.765
5Dasatinib99.6%0.4%87.970.699
6Tivozanib99.3%0.7%92.420.673
7Vandetanib98.5%1.5%95.740.723
8Repotrectinib98.3%1.8%84.210.608
9Bosutinib97.6%2.4%87.220.555
10Regorafenib97.6%2.4%95.990.719
11Gilteritinib96.7%3.3%88.970.506
12Sorafenib96.3%3.7%96.720.776
13Pralsetinib95.9%4.1%93.430.643
14Dabrafenib95.4%4.6%94.740.633
15Ripretinib94.8%5.2%92.950.674
16Lenvatinib94.3%5.7%97.740.726
17Erdafitinib93.5%6.5%95.710.737
18Midostaurin92.5%7.5%78.640.500
19Selpercatinib92.2%7.8%96.720.635
20Vemurafenib89.4%10.6%96.490.598

Paralog block

No paralog group registered for this kinase.

EMT expression

  • Mesenchymal log2(TPM+1): 4.62
  • Epithelial log2(TPM+1): 0.94
  • Fold change: 3.68
  • Status: Upregulated

High-confidence drugs

  1. Nilotinib — inh 99.7% · KISS 51.08
  2. Imatinib — inh 87.7% · KISS 50.65
  3. Sorafenib — inh 96.3% · KISS 49.49

Selectivity landscape vs inhibition on DDR2

Each point is one of the 92 approved drugs; color = inhibition % on DDR2.

Mutation lollipop

Cancer-associated mutations plotted by residue position. Marker size + color scale with the number of distinct cancer reports.

Variants (2)

Mutation × cancer associations

MutationCancerOrganSource
T654Mcarcinoma_lungLungref
N456Scarcinoma_lungLungref

3D structure

Embedded NGL viewer pulls a representative PDB entry (or AlphaFold model if no experimental structure is registered). Heavy bundle — loaded only on demand.

Annotations

Sign in to read and post annotations.

Loading…